Genetic testing can now point doctors toward drugs that may work against a patient's specific tumor, but insurance coverage often has not caught up, leaving patients with rare cancers to fight for medicines approved for other conditions, KFF Health News reported this week. Taken together, rare cancers make up about a quarter of all U.S. cancers, according to the National Cancer Institute.
The report centers on Mason Henderson, a 21-year-old from southeastern Texas with a brain tumor so rare that the World Health Organization named it only in 2021. After chemotherapy failed and a clinical trial in New York City did not stop the cancer, his doctors turned to Lynparza, a drug made by AstraZeneca and Merck and approved by the FDA in 2014 for ovarian cancer, based on the genetic features of his tumor.
His pharmacy benefit manager, Liviniti, refused coverage. Two weeks after the refusal, the company explained that Lynparza "is not approved for the diagnosis provided." Out of pocket, the drug would have cost about $8,700 a month, his mother said. After six weeks of appeals and a public social media campaign by his mother, AstraZeneca's patient assistance program shipped the drug.
Gene-Guided Treatment Outpaces Coverage Rules
Insurers generally decide whether to pay for a drug based on its FDA label and expert treatment guidelines. Rare cancers often have neither a targeted FDA-approved option nor a guideline, even when molecular tests suggest what might work.
"They have no guidelines for his cancer," Henderson's mother, Tabitha Lowe, told KFF Health News in March. "They're discriminating against him because his cancer is so rare."
The FDA has begun approving some drugs based on a tumor's genetic change rather than where in the body the cancer started. These so-called tissue-agnostic therapies, described in the National Cancer Institute's overview, remain a small minority of cancer drugs, even as more oncologists order tumor sequencing for their patients. The FDA issued draft guidance on developing these drugs in 2022.
Delays carry real weight in aggressive cancers. Henderson's prescription was written January 16 and refused January 30, and the drug did not arrive until March, after his mother posted about his case on social media and tagged the drugmaker, the benefit manager, and the county board that had denied reimbursement.
His case also showed how a family's plan structure matters. His coverage came through Jefferson County, Texas, where his stepfather works, and the family appealed to the county after the benefit manager's refusal. That appeal was also denied.
The Evidence Behind Off-Label Targeted Drugs
The science is promising but uneven. Doctors prefer to base treatment decisions on large clinical trials, but trials of that size will likely never be done for a cancer as rare as Henderson's. Jessica Schulte, a neuro-oncologist at NYU Langone Health who helped treat him, sees only a few patients with his tumor type each year.
Research programs are trying to fill the gap. The American Society of Clinical Oncology's TAPUR study, launched in 2016, gives patients with advanced cancer access to targeted drugs outside their approved uses and tracks the results. Findings from studies like TAPUR can lead to changes in treatment guidelines, which often open a path to insurance payment.
Not all experts agree that tumor genetics should drive treatment. Some oncologists caution that the evidence does not yet show that sequencing-guided treatment improves survival for most patients. The KFF Health News report does not show that faster access would have changed Henderson's outcome.
Patients and Families Facing a Denial
The heaviest burden falls on adolescents and young adults with rare tumors, people with cancers excluded from clinical trials, and families whose plans lack specialist reviewers. Brain cancers are especially hard to study because drugs must cross the blood-brain barrier and the number of patients is small.
Families facing a denial can ask the oncologist for a detailed letter of medical necessity that cites published case reports and the tumor's genetic results. They can request a peer-to-peer call between the treating doctor and the insurer's reviewer, ask for an expedited appeal when a delay could seriously harm the patient, and request that any outside reviewer be a specialist in the relevant cancer.
Drug manufacturers' patient assistance programs, hospital financial counselors, and clinical trial navigators can offer other routes while appeals proceed. Patients should not stop or change cancer treatment on their own while waiting for a coverage decision. Keeping copies of every denial letter and the plan's written reasons can speed each step of an appeal.
The toll of the process is part of the story. "Rare cancer patients are denied treatment simply because their cancers are rare," Lowe wrote in one of her social media posts, which were shared hundreds of times.
Change may come slowly. More tissue-agnostic approvals and guideline updates from studies like TAPUR could widen coverage over time. MedicalDaily will watch for insurer policy changes and new FDA approvals that could shorten the fight for patients with rare tumors.
Key Questions Answered
What is an off-label cancer drug? It is an FDA-approved drug prescribed for a cancer or condition not listed on its label, often based on a tumor's genetic features.
Why do insurers deny these drugs? Insurers typically rely on FDA labels and expert guidelines, which often do not cover rare cancers.
What are tissue-agnostic drugs? They are drugs approved for tumors with a specific genetic change, regardless of where in the body the cancer started. Only a small number have been approved.
What can patients do after a denial? Ask for a letter of medical necessity, a peer-to-peer review, an expedited appeal if a delay is dangerous, and a specialist outside reviewer.
Are there other ways to get the drug? Manufacturer patient assistance programs and clinical trials such as ASCO's TAPUR study may provide access, though eligibility varies.
Does genetic testing guarantee a drug will work? No. It can suggest a reasonable option, but evidence for many off-label uses in rare cancers remains limited.
Published by Medicaldaily.com
